Modification of the Indiana Pouch Ileo-Caecal Cutaneous Continent Urinary Diversion: Tubular Ileal Afferent Limb for Ureteral Anastomosis Has Low Stricture Rate and Allows Ileal Ureter Replacement

2021 ◽  
pp. 1-6
Author(s):  
Rolf von Knobloch ◽  
Marc Seybold ◽  
Hans Peter Fischer ◽  
Monika Kibele ◽  
Wasim Abdul Samad

<b><i>Objective:</i></b> The aim of the study was to introduce our new modification of the Indiana pouch with a refluxing ureteral anastomosis in a tubular afferent ileal segment of the ileo-caecal urinary reservoir. <b><i>Patients and Methods:</i></b> Between February 2008 and December 2020, we performed a total of 37 modified continent ileo-caecal pouches for urinary diversion when orthotopic bladder substitution was not possible. Hereby, we modified the Indiana pouch procedure with a new refluxing end-to-end ureteral anastomosis into an 8-cm afferent tubular ileal segment. <b><i>Results:</i></b> We performed the modified Indiana pouch in 27 women (73%) and 10 men (27%). The median age of the patients at time of operation was 64 years (43–80 years). To date, the average follow-up is 69 months (3–156 months). In 32/37 cases, we performed the new pouch procedure after radical cystectomy for muscle-invasive bladder cancer and in 1/37 cases after radical cystectomy for locally advanced prostate cancer. In 4 cases, the procedure was performed after total exenteration of the pelvis due to locally advanced bladder, colorectal, or gynaecological cancers. Ureteral anastomotic strictures were seen in 2/37 patients (5.4%) or 2/72 (2.8%) of renal units. <b><i>Conclusions:</i></b> Our modification of the Indiana pouch cutaneous continent urinary diversion with the ureteral anastomosis to a tubular segment of the pouch is easy to perform and effective in reducing the rate of ureteral anastomotic strictures. By lengthening, the afferent tubular ileal segment, it additionally allows easy ureteral replacement.

2014 ◽  
Vol 61 (1) ◽  
pp. 63-67
Author(s):  
Jovan Hadzi-Djokic ◽  
Vladan Andrejevic ◽  
Tomislav Pejcic ◽  
Miodrag Acimovic ◽  
Uros Babic ◽  
...  

Surgical treatment of invasive carcinoma of the bladder in males includes total cystectomy remo?al of the prostate, seminal vesicles, and the distal parts of the urethers and the pelvic lymph node dissection as well. At this moment it is not possible to recommend a particular type of urinary diversion, but today in clinical practice commonly used derivative are ileal orthotopic neobladder as the continent one and ileal conduit as non-continent urinary diversion. Continent urinary diversion after radical cystectomy are the result of the application of technological innovation in surgery, but also knowledge, imagination and skill of well trained urologist. This type of operation significantly improves the quality of life in patients who underwent radical cystectomy, and the proposal is to operate when- ever there is a possibility for this type of procedure. Also it is very important, during surgery to respect oncological principles, of complete removal of tumorous tissue and that the functional principle of ensuring that the patients have daytime and also nighttime continence later on after the surgery.


2003 ◽  
Vol 2 (1) ◽  
pp. 168
Author(s):  
E. Müller ◽  
D. Echtle ◽  
D. Kontaxis ◽  
D. Frohneberg

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. TPS504-TPS504 ◽  
Author(s):  
Andrea B. Apolo ◽  
Jonathan E. Rosenberg ◽  
William Y. Kim ◽  
Ronald C. Chen ◽  
Guru Sonpavde ◽  
...  

TPS504 Background: Patients with high-risk MIBC have a poor prognosis. Radical cystectomy remains the standard treatment. Yet despite substantial improvements in surgical techniques, mortality from metastatic recurrence remains high. A large number of MIBC patients are ineligible for cisplatin-based chemotherapy or have persistent muscle-invasive disease despite neoadjuvant chemotherapy (NAC). Pembrolizumab, a PD-1 inhibitor, has demonstrated significant activity and is FDA-approved for patients with advanced/chemotherapy-refractory metastatic urothelial carcinoma. We hypothesize that pembrolizumab given post-cystectomy will improve overall survival (OS) and disease-free survival (DFS) in patients with high-risk MIBC. Methods: Patients must have histologically confirmed muscle-invasive urothelial carcinoma of the bladder or upper tract, have received NAC and have ≥ pT2 and/or pN+ at surgery or be cisplatin-ineligible and have ≥ pT3 and/or pN+ at surgery or have declined adjuvant cisplatin-based therapy and have ≥ pT3 and/or pN+ at surgery. Surgery could be radical cystectomy, nephrectomy, or ureterectomy. Patients are stratified by pathologic stage, central PD-L1 status, and prior NAC. Patients are randomized to receive pembrolizumab 240 mg every 3 weeks for 1 year, or observation. The dual primary objectives are to determine DFS and OS. Secondary objectives are to determine DFS and OS in PD-L1-positive and -negative patients and assess safety. Correlative objectives are to determine whether 12 immune gene signatures, tumor molecular subtypes, diversity of T-cell receptor (TCR) clonotypes, persistence of TCR clonotypes, tumor and neoantigen burden, HLA subtypes, and plasma HGF and VEGF levels with IL-10 and IL-17 are associated with OS and DFS. Quality of Life Correlative objectives are to compare health-related quality of life as assessed by the EORTC QLQ-C30. Clinical trial information: NCT03244384.


2001 ◽  
pp. 1863-1866 ◽  
Author(s):  
INGOLF T??RK ◽  
SERDAR DEGER ◽  
BJ??RN WINKELMANN ◽  
BERND SCH??NBERGER ◽  
STEFAN A. LOENING

Urology ◽  
2004 ◽  
Vol 64 (5) ◽  
pp. 935-939 ◽  
Author(s):  
Serdar DeGer ◽  
Robert Peters ◽  
Jan Roigas ◽  
Andreas H. Wille ◽  
Ingolf A. Tuerk ◽  
...  

2018 ◽  
Vol 24 (1) ◽  
pp. 12
Author(s):  
StephenOdunayo Ikuerowo ◽  
OlufemiO Ojewuyi ◽  
MuftauJimoh Bioku ◽  
AbimbolaAyodeji Abolarinwa ◽  
OlufunmiladeAkinfolarin Omisanjo

Sign in / Sign up

Export Citation Format

Share Document